SLiPS study (Study of LIragultide on decreasing Parenteral Support)
Research type
Research Study
Full title
Pilot study of the GLP-1 agonist, Liraglutide, on decreasing parenteral support requirements in short bowel patients.
IRAS ID
218490
Contact name
James Willsmore
Contact email
Sponsor organisation
Imperial College London
Eudract number
2016-004797-18
Duration of Study in the UK
0 years, 8 months, 8 days
Research summary
Short bowel is one of the main causes of chronic intestinal failure. It is a condition whereby a large section of small bowel is surgically removed as a direct result of conditions including inflammatory bowel disease, or trauma. It is defined by loss of absorptive capacity such that there is an inability to maintain proper hydration, protein-energy, fluid, electrolyte or micronutrient balances when on a conventionally accepted normal diet. The normal management for short bowel patients, is long-term or lifelong parenteral support (PS) in combination with dietary modification, agents to reduce intestinal secretions and agents to reduce the speed of transit of food through the remaining intestine.
PS is a high cost treatment of between £95 to £235 per day. PS also carries with it a significant morbidity and mortality, with a 10-year survival rate in the UK at 59%-71%. This is both as a direct result of the nutrition itself, e.g. severe liver dysfunction, but also as a consequence of the indwelling central venous catheter, e.g. catheter related blood stream infections and blood cluts.
Immediately after intestinal resection, a spontaneous adaptation process starts to occur in an attempt both to increase the surface area of absorption, and to reduce intestinal transit speed. This is promoted by a variety of gut hormones, including the glucagon-like peptides GLP-1 and GLP-2.
GLP-1 is a 31 amino acid peptide secreted by L cells in the ileum (a part of the small intestine) and appears to be beneficial in preliminary metabolic studies for patients with short bowel by reducing secretions and transit speed, however there is now a need for a clinical pilot study to be undertaken. We propose an investigator-led pilot study of liraglutide, a GLP-1 analogue, on a cohort of patients with short bowel to assess if GLP-1 decreases parenteral support requirements.REC name
London - Brighton & Sussex Research Ethics Committee
REC reference
17/LO/0945
Date of REC Opinion
26 Jun 2017
REC opinion
Further Information Favourable Opinion